top banner image  

topleft corner image     top right corner image
 


bullet

     top nav image

     

J Am Coll Cardiol Intv, 2008; 1:202-209, doi:10.1016/j.jcin.2007.12.006
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Doyle, B. J.
Right arrow Articles by Rihal, C. S.
PubMed
Right arrow Articles by Doyle, B. J.
Right arrow Articles by Rihal, C. S.

Clinical Research

Major Femoral Bleeding Complications After Percutaneous Coronary Intervention

Incidence, Predictors, and Impact on Long-Term Survival Among 17,901 Patients Treated at the Mayo Clinic From 1994 to 2005

Brendan J. Doyle, MB, BCh, Henry H. Ting, MD, MBA, Malcolm R. Bell, MBBS, FRACP, Ryan J. Lennon, MS, Verghese Mathew, MD, Mandeep Singh, MD, David R. Holmes, MD, Charanjit S. Rihal, MD*

Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.

* Reprint requests and correspondence: Dr. Charanjit S. Rihal, Director, Cardiac Catheterization Laboratory, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. (Email: rihal.charanjit{at}mayo.edu).

Objectives: The purpose of this study was to evaluate secular trends and factors associated with major femoral bleeding after percutaneous coronary intervention (PCI) in routine clinical practice during the past decade and to assess the impact of these complications on outcomes including mortality.

Background: Significant changes in patient demographic data, adjunctive pharmacotherapy, and access site management have occurred during the coronary stent era. Trends in major vascular complications after PCI during this time have not been well characterized.

Methods: Consecutive patients who underwent transfemoral PCI from 1994 to 2005 at the Mayo Clinic (n = 17,901) were studied. Patients were divided into 3 groups: Group 1 (1994 to 1995, n = 2,441); Group 2 (1996 to 1999, n = 6,207); and Group 3 (2000 to 2005, n = 9,253).

Results: The incidence of major femoral bleeding complications decreased (from 8.4% to 5.3% to 3.5%; p < 0.001). Reductions in sheath size, intensity and duration of anticoagulation with heparin, and procedure time were observed (p < 0.001), and multivariate analysis confirmed each as an independent predictor of complications (p < 0.001). Adverse outcomes of major femoral bleeding included prolonged hospital stay (mean 4.5 vs. 2.7 days; p < 0.0001) and increased requirement for blood transfusion (39% vs. 4.7%; p < 0.0001). Major femoral bleeding and blood transfusion were both associated with decreased long-term survival, driven by a significant increase in 30-day mortality (p < 0.001 for both).

Conclusions: We noted a marked decline in the incidence of major femoral bleeding after PCI over the past decade. Mortality associated with these bleeding complications and with blood transfusion remains a significant issue.

Abbreviations and Acronyms
  ACT = activated clotting time
  BMI = body mass index
  CI = confidence interval
  GP = glycoprotein
  MI = myocardial infarction
  OR = odds ratio
  PCI = percutaneous coronary intervention






 
   
 
home link current link search link archive link topics link cardiology careers link